Expanding Revenue Sources through Contract Manufacturing and New Businesses
First written in FY2020. 3 of 15 entries say "Restated". Latest entry: FY2026-H1.
8 other companies' latest entry also says "Other".
- FY2026-H1Updated contract manufacturing and other revenue for the interim periodAnnual report
「The “Other” category consists of fees related to contract manufacturing and related activities for prescription drugs and co-promotion agreements (¥1,063 million in the previous interim accounting period and ¥1,415 million in the current interim accounting period), and rental income from real estate (¥59 million in the previous interim accounting period and ¥53 million in the current interim accounting period).」
Fees from contract manufacturing and related activities and co-promotion agreements for the interim period were ¥1,415 million, up from ¥1,063 million in the same period of the previous year. - FY2025-H1Updated contract manufacturing and other revenue for the interim periodAnnual report
「The “Other” category consists of fees related to contract manufacturing and related activities for prescription drugs and co-promotion agreements (¥1,443 million in the previous interim accounting period and ¥1,063 million in the current interim accounting period), and rental income from real estate (¥82 million in the previous interim accounting period and ¥59 million in the current interim accounting period).」
Fees from contract manufacturing and related activities and co-promotion agreements for the interim period were ¥1,063 million, down from ¥1,443 million in the same period of the previous year. - FY2024RestatedAnnual report
「While making use of these assets, the company has begun promoting new businesses and fields in order to expand new sources of revenue, including contract manufacturing of products for other companies, use management resources more efficiently, and generate synergies such as reducing product cost ratios.」
The company continues to promote contract manufacturing by leveraging its existing facilities, brand strength, knowledge and experience, as well as new businesses and fields. - FY2024-Q3Updated contract manufacturing and other revenue for the cumulative third quarterAnnual report
「The “Other” category consists of fees related to contract manufacturing and related activities for prescription drugs and co-promotion agreements (¥2,036 million in the cumulative third quarter of the previous fiscal year and ¥2,372 million in the cumulative third quarter of the current fiscal year), and rental income from real estate (¥131 million in the cumulative third quarter of the previous fiscal year and ¥123 million in the cumulative third quarter of the current fiscal year).」
Fees from contract manufacturing and related activities and co-promotion agreements for the cumulative third quarter were ¥2,372 million, up from ¥2,036 million in the same period of the previous year. - FY2024-Q2Updated contract manufacturing and other revenue for the first halfAnnual report
「The "Other" category comprises contract manufacturing-related revenue for prescription pharmaceuticals and fees under co-promotion agreements (¥1,233 million in the cumulative second quarter of the previous fiscal year and ¥1,443 million in the cumulative second quarter of the current fiscal year), and rental income from real estate (¥87 million in the cumulative second quarter of the previous fiscal year and ¥82 million in the cumulative second quarter of the current fiscal year).」
Fees from contract manufacturing and related activities and co-promotion agreements for the cumulative second quarter were ¥1,443 million, up from ¥1,233 million in the same period of the previous year. - FY2024-Q1Updated contract manufacturing and other revenue for the first quarterAnnual report
「The "Other" category comprises contract manufacturing-related revenue for prescription pharmaceuticals and fees under co-promotion agreements (¥503 million in the cumulative first quarter of the previous fiscal year and ¥689 million in the cumulative first quarter of the current fiscal year), and rental income from real estate (¥43 million in both periods).」
Contract manufacturing-related revenue for prescription pharmaceuticals and other products and fees under co-promotion agreements amounted to ¥689 million in the cumulative first quarter of the current fiscal year, up from ¥503 million in the same period of the previous year. - FY2023-Q3Updated contract manufacturing and other revenue for the cumulative third quarterAnnual report
「Prescription pharmaceuticals and medical equipment 37,051 Other 2,168 Net sales 39,219 (Note) The "Other" category comprises revenue from contract manufacturing of prescription pharmaceuticals and other products and fees under co-promotion agreements (¥1,708 million in the cumulative third quarter of the previous fiscal year and ¥2,036 million in the cumulative third quarter of the current fiscal year), and rental income from real estate (¥131 million in both periods).」
"Other" revenue for the cumulative third quarter was ¥2,168 million, of which contract manufacturing revenue and fees under co-promotion agreements amounted to ¥2,036 million, up from ¥1,708 million in the same period of the previous year. - FY2023-Q2Updated contract manufacturing and other revenue for the first halfAnnual report
「Prescription pharmaceuticals and medical equipment 24,049 Other 1,321 Net sales 25,371 (Note) The "Other" category comprises revenue from contract manufacturing of prescription pharmaceuticals and other products and fees under co-promotion agreements (¥1,128 million in the cumulative second quarter of the previous fiscal year and ¥1,233 million in the cumulative second quarter of the current fiscal year), and rental income from real estate (¥87 million in both periods).」
The company disclosed that "Other" revenue for the cumulative second quarter was ¥1,321 million, of which ¥1,233 million comprised contract manufacturing revenue and fees under co-promotion agreements. - FY2023-Q1Updated contract manufacturing and other revenue for the first quarterAnnual report
「Prescription pharmaceuticals and medical equipment 11,820 Other 546 Net sales 12,367 (Note) The "Other" category comprises revenue from contract manufacturing of prescription pharmaceuticals and other products and fees under co-promotion agreements (¥664 million in the cumulative first quarter of the previous fiscal year and ¥503 million in the cumulative first quarter of the current fiscal year), and rental income from real estate (¥43 million in both periods).」
The company disclosed that "Other" revenue for the current first quarter was ¥546 million, of which ¥503 million comprised contract manufacturing revenue for prescription pharmaceuticals and other products and fees under co-promotion agreements. - FY2022RestatedAnnual report
「While making use of these assets, the company has begun promoting new businesses and fields in order to expand new sources of revenue, including contract manufacturing of products for other companies, use management resources more efficiently, and generate synergies such as reducing product cost ratios.」
The company continues to promote contract manufacturing and new businesses and fields by leveraging its existing manufacturing facilities, brand strength, knowledge and experience. - FY2022-Q3Disclosed contract manufacturing and other revenue for the cumulative third quarterAnnual report
「Prescription pharmaceuticals and medical equipment 36,431 Other 1,708 Pharmaceuticals segment net sales 38,140 (Note) The "Other" category comprises revenue from contract manufacturing and fees under co-promotion agreements.」
Of the Pharmaceuticals segment net sales of ¥38,140 million for the cumulative third quarter, the company disclosed that ¥1,708 million was classified as "Other" and includes contract manufacturing revenue and fees under co-promotion agreements. - FY2022-Q2Disclosed contract manufacturing and other revenue for the first halfAnnual report
「Prescription pharmaceuticals and medical equipment 23,750 Other 1,128 Pharmaceuticals segment net sales 24,879 (Note) The "Other" category comprises revenue from contract manufacturing and fees under co-promotion agreements.」
Of the Pharmaceuticals segment net sales of ¥24,879 million, the company disclosed that the ¥1,128 million classified as "Other" includes contract manufacturing revenue and fees under co-promotion agreements. - FY2022-Q1Disclosed the breakdown of contract manufacturing and other revenueAnnual report
「Pharmaceuticals business Disaggregated revenue from contracts with customers (Unit: ¥ million) Cumulative first quarter Prescription pharmaceuticals and medical equipment 11,892 Other 664 Pharmaceuticals segment net sales 12,556 (Note) The "Other" category comprises revenue from contract manufacturing and fees under co-promotion agreements.」
Of the Pharmaceuticals segment net sales of ¥12,556 million, the company disclosed that the ¥664 million classified as "Other" includes contract manufacturing revenue and fees under co-promotion agreements. - FY2021RestatedAnnual report
「While making use of these assets, the company has begun promoting new businesses and fields in order to expand new sources of revenue, including contract manufacturing of products for other companies, use management resources more efficiently, and generate synergies such as reducing product cost ratios.」
The company continues to promote contract manufacturing and new businesses and fields by leveraging its existing manufacturing facilities, brand strength, knowledge and experience. - FY2020First statedAnnual report
「While making use of these assets, the company has begun promoting new businesses and fields in order to expand new sources of revenue, including contract manufacturing of products for other companies, use management resources more efficiently, and generate synergies such as reducing product cost ratios.」
The disclosure states that the company has begun promoting contract manufacturing for other companies and new businesses and fields by leveraging its existing manufacturing facilities, brand strength, knowledge and experience.